Like Drugs, Hate Cancer, This might be a play for you.

2017年1月20日

Potential positive news over a new cancer drug that passing phase 2 over the next few weeks or quarters may act as a catalyst for a short squeeze. Announced that they are "set to sit down with the FDA for an end of phase 2 face-to-face meeting early this quarter." Will be monitoring for an entry above the current resistance level of 6.00 to break the downtrend since November. Link for the article is below. Days to cover is currently 26 according to the Wall Street Journal. The referenced article was written on Jan 12th and the CMF has a positive divergence since that date. Additionally the stock has had high volume days on the 11th 12th and 13th recently. 12 month price target analyst consensus is 14 from NASDAQ info.

If you think I am over looking something please let me know, as I am new in trying to locate these plays.

insidermonkey.com/blog/highlighting-ziopharm-oncology-inc-ziop-as-a-catalyst-play-this-quarter-517476/

nasdaq.com/symbol/ziop/analyst-research

wsj.com/mdc/public/page/2_3062-nasdaqshort-highlites.html

2017年1月20日

評論

Delete the that in the first sentence, guess that is what I get for not proof reading. Anyways, even though the recent downtrend since November is likely caused from people in the know selling off before bad news indicating a negative outcome. I am taking a potentially positive side due to the fact that the drug targets aggressive brain tumors and the treatment could be applied to other forms of cancers if it is tolerable as it utilizes the immune system. So if this gets passed and used there are potential downstream applications.

2017年1月20日

評論

Thinking the prudent option is to take out put and call options to capture the move if a large enough one does happen.

2017年1月20日

評論

One more addendum, the drug is targeting aggressive brain tumors which result in high mortality rates. I have no knowledge on how the FDA operates but something tells me that it may have a greater chance of acceptance due to its targets as opposed to targeting type II diabetes. The tumor is glioblastoma multiforme which effects fewer than 200K people each year according to Google. It would be their ability to fine tune the drug that gives it its real potential, which is a replacement for radiation and chemotherapy if they can successfully harness the immune. Likely biased due to my optimistic view of the next generation cancer drug, but starting with targeting aggressive brain tumors is a brilliant idea, hopefully they will be able to target other types like breast cancer in the future.

2017年2月1日

評論

Long from 5.94